A user is developing a tool to track hair density, aiming to help those using treatments like minoxidil. They seek feedback on the tool's usefulness and are considering a low-cost model to cover expenses.
Breezula, a potential new hair loss treatment, may receive FDA approval soon, but it is expected to be a weaker alternative to finasteride and minoxidil. Concerns include its twice-daily application and possible side effects like HPA axis suppression.
Finasteride significantly lowers allopregnanolone levels, while dutasteride's effect is less clear and may vary. Some users speculate that dutasteride might be healthier for the brain due to its different inhibition pathways.
Dutasteride and finasteride are effective for many in reducing hair loss by lowering DHT levels, though results vary based on individual sensitivity and genetics. Higher doses of dutasteride may not significantly increase hair growth due to diminishing returns, and topical finasteride is suggested as an alternative for some.
A Dutasteride Simulator predicts serum dutasteride, serum DHT, and scalp DHT levels using models from research papers. It simulates various dosing schedules to determine steady-state effects and visualizes outcomes, including hair growth-related scalp DHT suppression.
A dutasteride simulator predicts that daily 0.5 mg dosing results in higher DHT suppression compared to less frequent dosing. Twice-weekly dutasteride may be as effective as finasteride 5 mg, providing a balance between efficacy and ease of use.
Choosing hair loss treatments is challenging due to concerns about side effects from finasteride and minoxidil. Users suggest starting with topical treatments and gradually increasing dosage, while some recommend oral finasteride for its effectiveness despite potential side effects.
There is concern about a potential ban on finasteride in the EU, but many believe it is unlikely unless serious side effects are found. Users rely on finasteride for hair loss and other health benefits, and a petition has been created to oppose any restrictions.
AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.
The conversation is about overcoming fear of finasteride/dutasteride for hair loss treatment. Users suggest starting with a small supply, noting side effects are rare and reversible, and emphasize personal comfort and confidence.
A user shared a video suggesting that 0.5mm microneedles are most effective for hair growth. Other users mentioned different microneedle lengths and advised consulting a dermatologist for personalized treatment.
The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.
A user shared their hair loss treatment progress, using 5% Minoxidil twice daily, 0.5 mg Finasteride daily, and a 1.5 mm dermaroller weekly. They started with a 1 mm dermaroller in May 2022.
The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.
A user is starting treatment for hair loss with topical minoxidil, oral finasteride, and is considering adding topical latanoprost but is unsure about the application frequency and method for latanoprost. They are seeking advice from others with experience using these treatments.
The conversation is about the lack of updates on GT20029, a potential hair loss treatment, and the user considering using dutasteride or RU58841 instead of minoxidil/finasteride due to the long duration of the latter treatments.
The conversation discusses Verteporfin as a potential hair loss treatment, with trials by Dr. Bargouthi and Dr. Bloxham mentioned, and a suggestion to follow updates on the Hair Restoration Network site or YouTube. Preliminary results are positive, but one user is skeptical, calling it "snake oil."
The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.
The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.
The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.
A user shared their successful hair loss journey using finasteride for five years and minoxidil for two years, which stabilized and improved their hair condition. They experienced some shedding with minoxidil but found the routine manageable and are open to future treatments like dutasteride if needed.
The post is a humorous take on the author's experience with hair loss and using finasteride for six months. The conversation includes discussions about hair loss, treatments like finasteride, and personal experiences with baldness.
The conversation discusses the potential of GT20029 to stop hair loss and possibly regrow hair, considering the body's regenerative abilities. No specific treatments were mentioned due to the original post being removed.
The efficacy of taking 1mg finasteride three times a week instead of daily for hair loss, with some users arguing that it is just as effective because finasteride has a long half-life in the scalp tissue and lower doses have been shown to be effective. Other users suggest experimenting with various treatments such as minoxidil and finasteride to achieve best results.
Hair loss treatments advertised on Instagram are likely ineffective and considered scams. Effective treatments like Minoxidil and Finasteride don't need advertising due to high demand.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
A user shared their experience with Finasteride for hair loss, noting a significant reduction in DHT levels and a complete loss of libido without other side effects. Another user agreed, discussing the negative impact on sexual drive and criticizing the community's attitude towards discussing side effects.